AIM Vaccine Lists on Hong Kong Stock Exchange Main Board
Chinese vaccine producer AIM Vaccine Co., Ltd. commenced trading on the Main Board of the Stock Exchange of Hong Kong on October 6, 2022. The company was China's second-largest vaccine manufacturer by approved lot release volume in 2021, excluding COVID-19 vaccines.
AIM Vaccine Co., Ltd., a significant player in China's vaccine industry, began trading on the Main Board of the Stock Exchange of Hong Kong (SEHK) on October 6, 2022. The company, trading under stock code 06660.HK, ranked as China's second-largest vaccine manufacturer in terms of approved lot release volume for 2021, not including COVID-19 vaccines.
The company's shares closed their first trading day at HK$16.66, marking a 3.09% increase from the initial offering price. The listing was supported by a consortium of joint sponsors and lead managers, including Goldman Sachs (Asia) L.L.C. and China International Capital Corporation Hong Kong Securities Limited.
AIM Vaccine stated that its listing in Hong Kong represents a key milestone and the beginning of a new phase for the company's development. Moving forward, the company plans to continue seeking access to quality industry resources to expand and optimize its business operations. It aims to stay abreast of advanced platform technologies and innovation trends to accelerate the development of vaccine candidates.
The company further indicated its intention to solidify and expand its market leadership by enhancing sales and marketing efforts for its approved vaccine products and by commercializing new offerings. AIM Vaccine's stated mission is to develop and manufacture top-quality vaccines to safeguard global health and establish itself as a world-class vaccine company.